Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INZY Inozyme Pharma

Halted 06-30 16:00:00 EDT

4.00

+0.00

0.00%

High4.00	Low4.00	Vol0.00
Open4.00	D1 Closing4.00	Amplitude0.00%
Mkt Cap259.66M	Tradable Cap120.59M	Total Shares64.92M
T/O5.83M	T/O Rate0.00%	Tradable Shares30.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INZY","market":"US","secType":"STK","nameCN":"Inozyme Pharma","latestPrice":4,"timestamp":1751313600000,"preClose":4,"halted":3,"volume":0,"delay":0,"floatShares":30148186,"shares":64915697,"eps":-1.682199,"marketStatus":"Halted","change":0,"latestTime":"06-30 16:00:00 EDT","open":4,"high":4,"low":4,"amount":5834075.230881,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.682199,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":4,"volumeRatio":0},"requestUrl":"/m/hq/s/INZY","defaultTab":"news","newsList":[{"id":"2578678144","title":"BioMarin Raises 2025 Revenue Guidance as PALYNZIQ and VOXZOGO Sales Climb 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578678144","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578678144?lang=en_us&edition=fundamental","pubTime":"2025-10-28 04:03","pubTimestamp":1761595424,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical Inc. reported operating cash flows totaling $369 million for the third quarter of 2025, and $728 million in year-to-date operating cash flows. Total cash, cash equivalents, and investments were $2.0 billion as of September 30, 2025, compared to $1.66 billion at December 31, 2024. The company updated its 2025 full-year financial guidance to reflect acquired in-process research and development charges of $221 million on a pre-tax basis related to the acquisition of Inozyme. The company also revised its Non-GAAP Operating Margin and Non-GAAP Diluted EPS guidance to include the impact of these charges. Weighted-average diluted shares outstanding for Non-GAAP Diluted EPS guidance is approximately 200 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDLb6jG3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","BMRN","IE00B19Z3581.USD","BK4566","BK4139"],"gpt_icon":0},{"id":"2573964609","title":"BioMarin updates financial impact of Inozyme Pharma acquisition with estimated 221 million charge in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573964609","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573964609?lang=en_us&edition=fundamental","pubTime":"2025-10-08 05:18","pubTimestamp":1759871897,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical Inc. expects to record acquired in-process research and development  charges of approximately $221 million in the third quarter of 2025 following its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is estimated to impact both GAAP and Non-GAAP diluted earnings per share by about $1.10 each. BioMarin noted that these figures are preliminary and subject to final financial statement closing procedures for the quarter ended September 30, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL6B0qYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE0002270589.USD","INZY","BK4139","BMRN","IE00B19Z3581.USD","BK4566"],"gpt_icon":0},{"id":"2557339627","title":"BioMarin Reports Q2 2025 Revenue of $825M, GAAP EPS Up 124% Y/Y, Raises Full-Year 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2557339627","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557339627?lang=en_us&edition=fundamental","pubTime":"2025-08-05 04:02","pubTimestamp":1754337750,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical Inc. has reported strong financial results for the second quarter ended June 30, 2025. The company achieved total revenues of $825 million, marking a 16% year-over-year increase, or 17% at constant currency. The GAAP diluted earnings per share  rose significantly by 124% compared to the previous year, reaching $1.23. Additionally, the non-GAAP diluted EPS increased by 50% year-over-year to $1.44. BioMarin has also updated its full-year 2025 guidance, raising expectations for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS. The improved guidance reflects robust growth in patient demand across its portfolio and the company's strategic focus on enhancing profitability and cash flow to fuel further innovation and growth. In terms of business developments, BioMarin completed the acquisition of Inozyme in July 2025 and anticipates pivotal data from their lead indication in the first half of 2026. The company is also advancing its pipeline with BMN ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL5N4qJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY","BMRN"],"gpt_icon":0},{"id":"2548042620","title":"Inozyme Pharma Inc. Announces Delisting from Nasdaq and Deregistration of Shares Following Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2548042620","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548042620?lang=en_us&edition=fundamental","pubTime":"2025-07-01 21:26","pubTimestamp":1751376367,"startTime":"0","endTime":"0","summary":"Inozyme Pharma Inc. has announced a significant regulatory move involving its shares. Effective July 1, 2025, the company notified the Nasdaq Global Select Market of the completion of a merger, leading to the suspension of trading and delisting of its shares. Inozyme has requested Nasdaq to file a Form 25 with the SEC to remove the shares from listing and deregister them under the Securities Exchange Act of 1934. The company also intends to file a Form 15 with the SEC to terminate the registration of its shares and suspend reporting obligations under certain sections of the Exchange Act. This strategic decision marks a key development in Inozyme's corporate trajectory following the consummation of a merger.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL8tscmF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2548004287","title":"BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2548004287","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548004287?lang=en_us&edition=fundamental","pubTime":"2025-07-01 21:15","pubTimestamp":1751375756,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical  said Tuesday that it has completed its all-cash acquisition of Inozyme Pharma  for $270 million, or $4 per share.The company said the move strengthens its enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy in development for ENPP1 Deficiency-a rare genetic disease that affects blood vessels, soft tissues, and bones.The company said Inozyme shares have now been delisted from the Nasdaq Global Select Market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","BK4566","INZY","IE0002270589.USD","BK4139"],"gpt_icon":0},{"id":"2548501774","title":"Trading in risky penny stocks is booming. Why it could be a sign of trouble ahead for the market.","url":"https://stock-news.laohu8.com/highlight/detail?id=2548501774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548501774?lang=en_us&edition=fundamental","pubTime":"2025-07-01 04:03","pubTimestamp":1751313780,"startTime":"0","endTime":"0","summary":"A recent report by Goldman Sachs showed activity in shares priced at $1 or less hit a record on June 12 as a percentage of total U.S. market activity. Trading in penny stocks has exploded over the past few years, driven in part by individual investors' ever-expanding appetite for risky bets, as well as a few tantalizing wins.But amid the frenzied activity, some see signs of trouble ahead for the broader market.Recently, activity in the penny-stock space hit a new milestone, according to a report from Goldman Sachs Group. Equity strategists at the bank found that trading in shares worth less than $1 accounted for more than 47% of total volume across the U.S. equity market on June 12, the highest share of daily trading on record. Overall, daily volume in these names has roughly tripled since 2021, the Goldman team said.\"You're not going to 10x a blue chip overnight, but with a low-float penny stock, a press release or a big-volume day can turn a $","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648001328.SGD","LU0477156953.USD","BK4559","LU0154245756.USD","LU2471134523.USD","BK4608","LU0661504455.SGD","LU1974910355.USD","LU0048573561.USD","LU0130517989.USD","LU2125154778.USD","LU2106854487.HKD","LU2237443978.SGD","BK4550","LU0124676726.USD","LU0256863902.USD","LU0738911758.USD","LU1868836757.USD","LU2360032135.SGD","LU2456880835.USD","LU0154236417.USD","LU0390134368.USD","LU1153585028.USD","IE00BQXX3F31.USD","LU1868836591.USD","BK4516","IE00BSNM7G36.USD","LU2417539215.USD","IE00BFXG1179.USD","BK4141","BK4581","LU1267930227.SGD","HCTI","LU0052756011.USD","LU1791807156.HKD","LU2125154935.USD","LU0061475181.USD","LU1668664300.SGD","GB00BDT5M118.USD","ICE","LU2237443895.HKD","AMT","BK4534","INZY","BK4588","LU0251142724.SGD","LU1917777945.USD"],"gpt_icon":1},{"id":"2545710826","title":"Press Release: Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2545710826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545710826?lang=en_us&edition=fundamental","pubTime":"2025-06-21 05:00","pubTimestamp":1750453200,"startTime":"0","endTime":"0","summary":"BOSTON, June 20, 2025  -- Inozyme Pharma, Inc.  today announced that it has postponed its 2025 Annual Meeting of Stockholders , which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition  by BioMarin Pharmaceutical Inc. .If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take such further action as it deems appropriate to call and convene the Annual Meeting at a later date, including the establishment of a new record date for determining the stockholders entitled to vote at the Annual Meeting.Additional Information About the Acquisition and Where to Find It","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2540767092","title":"Inozyme Pharma Announces Transaction Bonuses for Key Executives Following Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2540767092","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540767092?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:36","pubTimestamp":1748864174,"startTime":"0","endTime":"0","summary":"Inozyme Pharma Inc., a Delaware-based company, has announced new compensation terms in light of its recent merger agreement with BioMarin Pharmaceutical, Inc. As part of the agreement, Inozyme's Board of Directors has approved transaction bonuses for key executives. Chief Financial Officer and Head of Business Development, Mr. Sanjay Subramanian, is set to receive a cash bonus of $350,000, while Dr. Matthew Winton, the Senior Vice President and Chief Operating Officer, will be awarded $320,000. These bonuses will be issued following the completion of the merger, contingent upon their continued employment until the closing date, with payments to be made within 30 days thereafter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inozyme Ph","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL8y1Pdh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4566","INZY","IE00B7SZLL34.SGD","BK4139","BMRN","IE00B19Z3B42.SGD","IE0002270589.USD"],"gpt_icon":0},{"id":"2536686517","title":"Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2536686517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536686517?lang=en_us&edition=fundamental","pubTime":"2025-05-19 19:30","pubTimestamp":1747654249,"startTime":"0","endTime":"0","summary":"Inozyme Pharma (INZY) has an average rating of Hold and mean price target of $6.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJF","INZY"],"gpt_icon":0},{"id":"2536570622","title":"U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2536570622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536570622?lang=en_us&edition=fundamental","pubTime":"2025-05-19 15:47","pubTimestamp":1747640865,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme PharmaMay 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Advansix","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nL8N3RR0BA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTSH","LU0957791311.USD","SGXZ81514606.USD","LZ","LU2471134952.CNY","INZY","SG9999002232.USD","KLAC","BK4534","LU2552382058.USD","IE00BFSS8Q28.SGD","SG9999018857.SGD","LU2089284900.SGD","SG9999003800.SGD","ASIX","SG9999015945.SGD","LU1917777945.USD","LRCX","STAA","BWIN","IE0005OL40V9.USD","BK4173","LU2458330243.SGD","LU2750360997.AUD","LU0109394709.USD","LU1127390331.HKD","LU0354030511.USD","BK4198","LU0266013472.USD","LU0316494557.USD","SG9999001424.SGD","LU0162691827.USD","LU2461242641.AUD","LU2552382132.HKD","LU0006306889.USD","LU0882574139.USD","ITT","LU0225284248.USD","LU0011850046.USD","SG9999014906.USD","LU2063271972.USD","LU2237443978.SGD","BIIB","IE00B4R5TH58.HKD","BP","SG9999017495.SGD","LU2602419157.SGD"],"gpt_icon":1},{"id":"2536705329","title":"Inozyme Pharma Cut to Equal-Weight From Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2536705329","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536705329?lang=en_us&edition=fundamental","pubTime":"2025-05-17 06:39","pubTimestamp":1747435140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INZY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 18:39 ET (22:39 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2536769346","title":"Sector Update: Health Care Stocks Rise Friday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2536769346","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536769346?lang=en_us&edition=fundamental","pubTime":"2025-05-17 01:53","pubTimestamp":1747418034,"startTime":"0","endTime":"0","summary":"Health care stocks were higher Friday afternoon, with the NYSE Health Care Index rising 1.5% and the Health Care Select Sector SPDR Fund  climbing 1.6%.The iShares Biotechnology ETF  added 1.3%.In corporate news, Johnson & Johnson  received approval from the UK's Medicines and Healthcare products Regulatory Agency for guselkumab to treat Crohn's disease and ulcerative colitis. The shares rose 1%.Novo Nordisk  stock fell 3% after the Danish drugmaker said Chief Executive Officer Lars Fruergaard Jorgensen agreed to step down amid market challenges and share price declines.BioMarin Pharmaceutical  agreed to buy Inozyme Pharma  for $270 million. Inozyme shares more than doubled, and BioMarin rose 1.9%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999002224.SGD","LU1732799900.SGD","IE0002270589.USD","INZY","LU1059921491.USD","LU2347655156.SGD","IE00BFTCPJ56.SGD","BK4504","LU2129689431.USD","LU1674673428.USD","XLV","LU0154236417.USD","NVO.AU","IE00BJT1NW94.SGD","IE00BBT3K403.USD","LU1057294990.SGD","LU1244550577.SGD","JNJ","LU0345770993.USD","IE0009355771.USD","IE00B19Z3B42.SGD","LU0889566641.SGD","LU1914381329.SGD","NVO","LU1032466523.USD","LU1244550221.USD","LU2505996681.GBP","SG9999001440.SGD","IE00B3PB1722.GBP","IE00BKVL7J92.USD","BMRN","IE000M9KFDE8.USD","LU2505996509.AUD","LU0122379950.USD","IBB","LU1023059063.AUD","LU0345770308.USD","IE00BLSP4452.SGD","LU0985320562.USD","IE00BVYPNV92.GBP","IE00BGHQF631.EUR","IE00B1BXHZ80.USD","LU2602419157.SGD","SG9999002232.USD","IE00BVYPNW00.USD","LU0098860793.USD","LU0234570918.USD","LU2592432038.USD","IE00B4R5TH58.HKD","BK4559"],"gpt_icon":1},{"id":"2536458993","title":"Inozyme Pharma Cut to Hold From Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2536458993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536458993?lang=en_us&edition=fundamental","pubTime":"2025-05-17 01:07","pubTimestamp":1747415220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INZY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 13:07 ET (17:07 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2535317973","title":"Wells Fargo Downgrades Inozyme Pharma to Equal Weight From Overweight, $4 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2535317973","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535317973?lang=en_us&edition=fundamental","pubTime":"2025-05-16 23:49","pubTimestamp":1747410586,"startTime":"0","endTime":"0","summary":"Price: 3.95, Change: +2.53, Percent Change: +178.17","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INZY"],"gpt_icon":0},{"id":"2535317584","title":"Inozyme Shares More Than Double in Surge Toward BioMarin's Buyout Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2535317584","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535317584?lang=en_us&edition=fundamental","pubTime":"2025-05-16 23:44","pubTimestamp":1747410240,"startTime":"0","endTime":"0","summary":"Shares of Inozyme Pharma soared to near the $4 per-share price BioMarin Pharmaceutical said it would pay for the company.The stock more than doubled to $3.95 in late morning trading on Friday. It closed the market session on Friday at $1.42.BioMarin said Friday morning that it has agreed to buy Inozyme for $4 a share, or about $280 million in cash.The deal has been approved by the directors of both companies and is expected to close in the third quarter.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY","BMRN","IE00B19Z3B42.SGD","BK4139","IE00B19Z3581.USD","BK4566","IE0002270589.USD","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2535316771","title":"US Stocks Edge Higher; Consumer Sentiment Falls In May","url":"https://stock-news.laohu8.com/highlight/detail?id=2535316771","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535316771?lang=en_us&edition=fundamental","pubTime":"2025-05-16 22:22","pubTimestamp":1747405366,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45469503/us-stocks-edge-higher-consumer-sentiment-falls-in-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSSI","ZENV",".IXIC","BK4139","MNQmain","USAW.SI","AFMDQ","SQQQ","LGPS","BK4024","NVIW.SI","BK4137","TSYW.SI","BK4167","AFMD","QLD","BK4134","HCTI","PSQ","NQmain","TQQQ","BK4539","INZY","BK4023","QID","USJW.SI"],"gpt_icon":1},{"id":"2535972318","title":"Wedbush Downgrades Inozyme Pharma to Neutral From Outperform, Adjusts Price Target to $4 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2535972318","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535972318?lang=en_us&edition=fundamental","pubTime":"2025-05-16 21:26","pubTimestamp":1747402016,"startTime":"0","endTime":"0","summary":"Inozyme Pharma (INZY) has an average rating of buy and mean price target of $12.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INZY"],"gpt_icon":0},{"id":"2535645390","title":"BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, Charter Communications, Vistra","url":"https://stock-news.laohu8.com/highlight/detail?id=2535645390","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535645390?lang=en_us&edition=fundamental","pubTime":"2025-05-16 21:06","pubTimestamp":1747400783,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, Charter Communications, VistraEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL6N3RO0GP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357305700.SGD","BK4212","IE00B19Z8W00.USD","LU1069347547.HKD","LU2028103732.USD","LU2324357040.USD","IE00B4JS1V06.HKD","LU2491049909.HKD","SGXZ99366536.SGD","LAC","LU0058720904.USD","LU0980610538.SGD","LU0965508806.USD","LU2360032135.SGD","LU0320765059.SGD","BK4585","LU0654597011.USD","IE0005OL40V9.USD","BMRN","LU1854104046.USD","LU0256863811.USD","EL","BK4581","LU0251132253.USD","LU2361044865.SGD","LU2089984988.USD","IE00B19Z3581.USD","INZY","LU0211326839.USD","AU","LU1854103824.USD","VST","LU1267930227.SGD","SENS","LU1023059063.AUD","LU1674673691.USD","SG9999014906.USD","LU0965509283.SGD","LU0795875086.SGD","LU0965509010.AUD","FLO","NEM","LU1778281490.HKD","LU1084165304.USD","BK4100","STZ","LU0689472784.USD","CHTR","IE00B19Z9505.USD"],"gpt_icon":1},{"id":"2535939752","title":"BUZZ-Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin","url":"https://stock-news.laohu8.com/highlight/detail?id=2535939752","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535939752?lang=en_us&edition=fundamental","pubTime":"2025-05-16 20:50","pubTimestamp":1747399846,"startTime":"0","endTime":"0","summary":"BUZZ-Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin** Shares of rare disease therapy developer Inozyme Pharma INZY.O rise 179% to $3.96 premarket ** BioMarin Pharma BMRN.O says that it has entered into an agreement to buy Inozyme Pharma for $4 per share in an all-cash transaction for a total consideration of around $270 million** The deal is expected to close in Q3 2025 ** The deal will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed to treat a rare genetic disorder affecting blood vessels, soft tissues and bones, BMRN says** As of last close, INZY down 48.7% YTD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL4N3RO0Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4139","IE00B19Z3581.USD","BK4566","BMRN","INZY","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2535539145","title":"BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535539145","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535539145?lang=en_us&edition=fundamental","pubTime":"2025-05-16 19:55","pubTimestamp":1747396547,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical  said Friday that it has agreed to acquire Inozyme Pharma  at $4 per share in cash for a total price of $270 million.The biotech company said the deal is expected to close in Q3, which is contingent on regulatory approval, completion of a tender offer, and other customary closing conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IE0002270589.USD","IE00B19Z3581.USD","BK4566","IE00B7SZLL34.SGD","INZY","BMRN","IE00B19Z3B42.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inozyme.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0025},{"period":"1year","weight":0.3423},{"period":"ytd","weight":0.444}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.22291},{"month":2,"riseRate":0.4,"avgChangeRate":-0.005308},{"month":3,"riseRate":0.4,"avgChangeRate":0.137262},{"month":4,"riseRate":0.2,"avgChangeRate":-0.059967},{"month":5,"riseRate":0.6,"avgChangeRate":0.490343},{"month":6,"riseRate":0.6,"avgChangeRate":0.0394},{"month":7,"riseRate":0.2,"avgChangeRate":-0.005239},{"month":8,"riseRate":0.2,"avgChangeRate":0.036393},{"month":9,"riseRate":0,"avgChangeRate":-0.135388},{"month":10,"riseRate":0,"avgChangeRate":-0.227258},{"month":11,"riseRate":0.4,"avgChangeRate":-0.05305},{"month":12,"riseRate":0.4,"avgChangeRate":-0.09901}],"exchange":"NASDAQ","name":"Inozyme Pharma","nameEN":"Inozyme Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inozyme Pharma(INZY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inozyme Pharma,INZY,Inozyme Pharma股票,Inozyme Pharma股票老虎,Inozyme Pharma股票老虎国际,Inozyme Pharma行情,Inozyme Pharma股票行情,Inozyme Pharma股价,Inozyme Pharma股市,Inozyme Pharma股票价格,Inozyme Pharma股票交易,Inozyme Pharma股票购买,Inozyme Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inozyme Pharma(INZY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction